Teva Pharmaceutical Industries' Copaxone is by far the top-selling drug, bringing in $3.2 billion in U.S. sales in 2015.
The 2009 documentary offers a wealth of detail. Which is why it makes no sense that Genentech doesn't want you to see the damn thing.
Each of the approaches is valid and more ambitious than a great majority of the campaigns that preceded them.
Diabetes patients sue drugmakers over price increases; the FTC opens Mylan investigation; Fitbit to ramp up marketing
Here are six creative campaigns that use creativity to connect with the audience.
Despite their blockbuster status and distinction as the world's most widely prescribed class of drugs, statins may not be the best option for all patients with elevated low density lipoprotein (LDL) cholesterol levels.
Gilead forms network to encourage access to hep.-C drugs; Dentsu CEO to resign following the suicide of a staffer; BI to divest animal-health products
Allergan's board endorses its social contract with patients; drugmakers that market painkillers are hiring DEA officials; the FDA approves new Biogen drug
More barriers separate doctors and patients than ever before, from rising costs and time constraints to electronic health records and smartphones.
Given its modern-day ubiquity, it's easy to forget that pharma DTC didn't exist until the 1980s rolled around.
Sharecare acquires virtual-reality developer; Novo Nordisk to cut 1,000 jobs; the FDA approves Medtronic's automated insulin pump
Really? Is this the new healthcare math — the fewer the insurance companies, the greater the competition and the lower the premiums?
Discovering Meaningful Insights in Patient Journeys: Identifying Hidden Patterns Using Advanced AnalyticsSeptember 21, 2016
During this seminar, attendees will learn how advanced data analytics can be applied to gain a measurable competitive advantage.
In this webcast, TrialCard VP of analytic services Paul LeVine and senior analytic consultant Robert Leedom underscore how affordability programs provide the ideal venue for focusing on adherence issues.
In this sponsored podcast, MM&M's Larry Dobrow speaks with Robert Leedom, senior analytics consultant at TrialCard, and Paul LeVine, VP of analytic services for TrialCard, about how to reach patients by leveraging brand data.
The latest TV campaign from Mars features a woman with cerebral palsy joking about her love life.
The availability of online medical information is changing the way doctors share and receive information — both among themselves and with their patients.
Will this payer pressure pose an existential threat to co-pay cards even though patients love them?
Many patients find it difficult to ask questions of their physician.
It's unlikely that pharma will ever achieve the degree of consumer love directed at Amazon and Apple but the shift taking place will open up doors for pharma organizations.
The power of hackathons is now magnified because of the power of the internet and social media, giving both patients and healthcare professionals a global platform for their voices.
Imagine if the agencies pitching us mocha lattes faced these consumer beliefs: The latte will hurt when I drink it. The latte might leave me with a rash or cause me to vomit.
In the webinar, 5 Keys to Success in the New Patient Economy, you'll learn tips and strategies for transforming your patient engagement model.
Drugmakers test out virtual reality, partner with companies like Spotify, and go for the cinematic at Cannes Lions.
Despite the increasing importance of the CIO post, top technology professionals still find it hard to break into the uppermost ranks at life-sciences companies.
In partnership with inVentiv Health, MM&M found a millennial doctor to ask about her frustrations with the existing pharma marketing model to her willingness to text patients.
The truth is, biopharma marketing and behavioral psychology have a lot in common. Ultimately, both aim to nudge people to make a medical or lifestyle change that could positively impact their health.
Where are the discussions about applying proven behavior change models or the principles of adult learning and health literacy?
It's a common refrain in healthcare and among patients, providers, and payers: Despite massive investment, no one has figured out how to change human behavior.
Maybe we have just forgotten the true reason why marketing exists in organizations.
- Top 25 rare disease brands, by sales
- Five things for pharma marketers to know: Monday, February 13, 2016
- Orphan drugs face criticism on prices — and from patients
- Five things for pharma marketers to know: Thursday, February 16, 2017
- Five things for pharma marketers to know: Wednesday, February 15, 2017